Comparative Pharmacology
Head-to-head clinical analysis: EOHILIA versus KENALOG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EOHILIA versus KENALOG.
EOHILIA vs KENALOG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EOHILIA (budesonide) is a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as cytokines and arachidonic acid metabolites, thereby reducing inflammation in the esophagus.
Triamcinolone acetonide is a synthetic corticosteroid with potent glucocorticoid and weak mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, decreased release of arachidonic acid, and reduced synthesis of prostaglandins and leukotrienes. It also suppresses cytokine production and immune cell migration.
For adults: 0.5 mg/kg IV every 2 weeks, infused over 60 minutes. Maximum single dose: 40 mg.
Kenalog (triamcinolone acetonide) 40-80 mg intramuscularly (deep gluteal) every 4 weeks; or 0.5-1 mg/kg intravenously every 24 hours (for acute conditions).
None Documented
None Documented
Terminal elimination half-life is 52 hours (steady state reached after 10-12 days of daily dosing)
Terminal half-life ~2-5 hours (triamcinolone acetonide); clinical duration prolonged due to crystalline depot formulation
Renal (70% unchanged drug), fecal (12%) and biliary (5%)
Renal (primarily as metabolites), ~30% unchanged; biliary/fecal minor (≤10%)
Category C
Category C
Corticosteroid
Corticosteroid